NCT00240097 - Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Intervention A: Irinotecan; Oxaliplatin; Neulasta

Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)

DRUG

Intervention B: Etoposide; Carboplatin; Neulasta

Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham